Theracryf (TCF)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

0.21p
   
  • Change Today:
    -0.013p
  • 52 Week High: 1.22
  • 52 Week Low: 0.21
  • Currency: UK Pounds
  • Shares Issued: 2,129.62m
  • Volume: 360,263
  • Market Cap: £4.53m
  • Beta: 0.01

Theracryf Overview

TheraCryf is a clinical stage therapeutics company developing a new generation of innovative therapeutics in oncology and behavioural brain disorders. TheraCryf’s strategy is to generate compelling data sets with a goal of partnering its programmes with mid-size to large pharma. The Company’s clinical asset is SFX-01, a patented sulforaphane-based medicine. Chronos’ neuropsychiatry assets use novel chemistry to address highly relevant targets in brain health and have composition of matter patent cover. The Group Company has the expertise to develop and commercialise the combined portfolio.

1 Day Chart

1 Day Chart

6 Month Chart

6 Month Chart

Financials

Latest F'cast
Div Yield 0.0% 0.0%
Div Cover n/a n/a
Op Mrgn -892.5% n/a
ROCE n/a  
Latest F'cast
P/E n/a n/a
PEG n/a n/a
Pr/Revenue 12.0 n/a
Pr/Book 2.0  
Latest F'cast
Revenue -9.1% n/a
PBT n/a n/a
EPS n/a n/a
DPS n/a n/a

Theracryf Fundamentals

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Mar-20 n/a (3.17) (2.07)p n/a n/a n/a n/a 0.0%
31-Mar-21 0.19 (3.21) (1.82)p n/a n/a n/a n/a 0.0%
31-Mar-22 n/a (3.17) (0.99)p n/a n/a n/a n/a 0.0%
31-Mar-23 0.44 (5.01) 1.47p 2.5 n/a n/a n/a 0.0%
31-Mar-24 0.40 (3.57) (1.14)p n/a n/a n/a n/a 0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Theracryf Company Announcements

Holding(s) in Company 21-Mar-2025 15:55 RNS
Holding(s) in Company 20-Mar-2025 15:33 RNS
Holding(s) in Company 20-Mar-2025 11:01 RNS

Latest Theracryf Director Deals

No deals were found in the last 28 days.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 3: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 4: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 5: Forecast figures based on normalised accounts.

 

Theracryf Market Data

Currency UK Pounds
Share Price 0.21p
Change Today -0.013p
% Change -5.56 %
52 Week High 1.22
52 Week Low 0.21
Volume 360,263
Shares Issued 2,129.62m
Market Cap £4.53m
Beta 0.01

Theracryf Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
45.43% below the market average45.43% below the market average45.43% below the market average45.43% below the market average45.43% below the market average
48.94% above the sector average48.94% above the sector average48.94% above the sector average48.94% above the sector average48.94% above the sector average
Price Trend
96.65% below the market average96.65% below the market average96.65% below the market average96.65% below the market average96.65% below the market average
91.84% below the sector average91.84% below the sector average91.84% below the sector average91.84% below the sector average91.84% below the sector average
Income Not Available
Growth
16.47% below the market average16.47% below the market average16.47% below the market average16.47% below the market average16.47% below the market average
29.03% below the sector average29.03% below the sector average29.03% below the sector average29.03% below the sector average29.03% below the sector average

Theracryf Dividends

No dividends found

Trades for 31-Mar-2025

Time Volume / Share Price
09:59 300,000 @ 0.21p
09:26 3,683 @ 0.21p
08:51 4,850 @ 0.21p
08:49 46,880 @ 0.21p
08:22 4,850 @ 0.24p

Theracryf Key Personnel

CEO Huw Jones
CFO Toni Hänninen

Top of Page